Biogen Inc. (NASDAQ:BIIB) EVP Adriana Karaboutis sold 262 shares of the business’s stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of $311.94, for a total transaction of $81,728.28. Following the completion of the transaction, the executive vice president now directly owns 7,579 shares in the company, valued at $2,364,193.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Adriana Karaboutis also recently made the following trade(s):
- On Monday, October 3rd, Adriana Karaboutis sold 380 shares of Biogen stock. The stock was sold at an average price of $313.00, for a total transaction of $118,940.00.
Biogen Inc. (NASDAQ:BIIB) opened at 309.70 on Thursday. Biogen Inc. has a 12-month low of $223.02 and a 12-month high of $333.65. The firm has a 50-day moving average price of $308.94 and a 200-day moving average price of $279.14. The company has a market cap of $67.86 billion, a P/E ratio of 18.09 and a beta of 0.95.
Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Thursday, July 21st. The biotechnology company reported $5.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.69 by $0.52. Biogen had a return on equity of 40.59% and a net margin of 33.97%. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.79 billion. During the same quarter in the previous year, the company posted $4.22 EPS. The company’s revenue was up 11.7% compared to the same quarter last year. On average, equities research analysts forecast that Biogen Inc. will post $20.10 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on BIIB. Vetr downgraded shares of Biogen from a “hold” rating to a “sell” rating and set a $265.77 price target on the stock. in a report on Monday, July 25th. BMO Capital Markets upped their price objective on shares of Biogen from $286.00 to $304.00 and gave the company a “market perform” rating in a report on Monday, August 1st. Piper Jaffray Cos. reaffirmed a “neutral” rating on shares of Biogen in a report on Wednesday, August 3rd. Credit Suisse Group AG set a $322.00 price objective on shares of Biogen and gave the company a “hold” rating in a report on Sunday, September 18th. Finally, Jefferies Group dropped their price objective on shares of Biogen from $323.00 to $316.00 and set a “hold” rating on the stock in a report on Wednesday. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $347.34.
Hedge funds have recently added to or reduced their stakes in the company. Strs Ohio increased its stake in Biogen by 10.6% in the second quarter. Strs Ohio now owns 303,272 shares of the biotechnology company’s stock worth $73,337,000 after buying an additional 29,114 shares during the last quarter. Boston Advisors LLC increased its position in Biogen by 2,223.4% in the second quarter. Boston Advisors LLC now owns 127,347 shares of the biotechnology company’s stock valued at $30,795,000 after buying an additional 121,866 shares in the last quarter. Artemis Investment Management LLP increased its position in Biogen by 203.9% in the second quarter. Artemis Investment Management LLP now owns 55,166 shares of the biotechnology company’s stock valued at $13,342,000 after buying an additional 37,015 shares in the last quarter. Nuveen Asset Management LLC increased its position in Biogen by 101.9% in the first quarter. Nuveen Asset Management LLC now owns 101,785 shares of the biotechnology company’s stock valued at $26,497,000 after buying an additional 51,375 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in Biogen during the first quarter valued at $33,233,000. 86.21% of the stock is currently owned by institutional investors and hedge funds.
Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.